The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis
Open accessAbstract
OBJECTIVE: To evaluate the efficacy and toxicity of methotrexate (MTX) monotherapy compared with MTX combination with non-biological disease-modifying antirheumatic drugs (DMARDs) in adults with rheumatoid arthritis. METHOD: A systematic review of randomised trials comparing MTX alone and in combination with other non-biological DMARDs was carried out. Trials were identified in Medline, EMBASE, the Cochrane Library and ACR/EULAR meeting abstracts. Primary outcomes were withdrawals for adverse events or lack of efficacy. RESULTS: A total of 19 trials (2025 patients) from 6938 citations were grouped by the type of patients randomised. Trials in DMARD naive patients showed no significant advantage of the MTX combination versus monotherapy; withdrawals for lack of efficacy or toxicity were similar in both groups (relative risk (RR) = 1.16; 95% CI 0.70 to 1.93). Trials in MTX or non-MTX DMARD inadequate responder patients also showed no difference in withdrawal rates between the MTX combo versus mono groups (RR = 0.86; 95% CI 0.49 to 1.51 and RR = 0.75; 95% CI 0.41 to 1.35), but in one study the specific combination of MTX with sulfasalazine and hydroxychloroquine showed a better efficacy/toxicity ratio than MTX alone with RR = 0.3 (95% CI 0.14 to 0.65). Adding leflunomide to MTX non-responders improved efficacy but increased the risk of gastrointestinal side effects and liver toxicity. Withdrawals for toxicity were most significant with ciclosporin and azathioprine combinations. CONCLUSION: In DMARD naive patients the balance of efficacy/toxicity favours MTX monotherapy. In DMARD inadequate responders the evidence is inconclusive. Trials are needed that compare currently used MTX doses and combination therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The combination of estimates from different experiments
Cochran, W. G. (1954) · Biometrics · doi:10.2307/3001666 · Cited by 5,380
Moher, D., Pham, B., Jones, A., Cook, D. J., Jadad, A. R., Moher, M., Tugwell, P., & Klassen, T. P. (1998) · The Lancet · doi:10.1016/s0140-6736(98)01085-x · Cited by 3,560
Wood, L., Egger, M., Gluud, L. L., Schulz, K. F., Jüni, P., Altman, D. G., Gluud, C., Martin, R. M., Wood, A. J. G., & Sterne, J. A. C. (2008) · BMJ · doi:10.1136/bmj.39465.451748.ad · Cited by 2,538
Updated Method Guidelines for Systematic Reviews in the Cochrane Collaboration Back Review Group
van Tulder, M., Furlan, A., Bombardier, C., & Bouter, L. (2003) · Spine · doi:10.1097/01.brs.0000065484.95996.af · Cited by 2,180
Self-citationThe Hazards of Scoring the Quality of Clinical Trials for Meta-analysis
Jüni, P. (1999) · JAMA · doi:10.1001/jama.282.11.1054 · Cited by 1,981
QUANTITATIVE METHODS IN THE REVIEW OF EPIDEMIOLOGIC LITERATURE1
GREENLAND, S. (1987) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a036298 · Cited by 1,644
Systematic Review: Why sources of heterogeneity in meta-analysis should be investigated
Thompson, S. G. (1994) · BMJ · doi:10.1136/bmj.309.6965.1351 · Cited by 1,017
Formulating Questions and Locating Primary Studies for Inclusion in Systematic Reviews
Counsell, C. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-5-199709010-00008 · Cited by 505
Evaluation of old and new tests of heterogeneity in epidemiologic meta-analysis
Takkouche, B., Cadarso-Suarez, C., & Spiegelman, D. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009981 · Cited by 380
Kleijnen, J., & Knipschild, P. (1992) · Pharmaceutisch Weekblad Scientific Edition · doi:10.1007/bf01977620 · Cited by 89
Cited by
Smolen, J. S., Landewé, R., Breedveld, F. C., Buch, M., Burmester, G., Dougados, M., Emery, P., Gaujoux-Viala, C., Gossec, L., Nam, J., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204573 · Cited by 1,763
2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Fraenkel, L., Bathon, J. M., England, B. R., St.Clair, E. W., Arayssi, T., Carandang, K., Deane, K. D., Genovese, M., Huston, K. K., Kerr, G., et al. (2021) · Arthritis Care & Research · doi:10.1002/acr.24596 · Cited by 1,341
2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Fraenkel, L., Bathon, J. M., England, B. R., St.Clair, E. W., Arayssi, T., Carandang, K., Deane, K. D., Genovese, M., Huston, K. K., Kerr, G., et al. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41752 · Cited by 1,042
Rainsford, K. D., Parke, A. L., Clifford-Rashotte, M., & Kean, W. F. (2015) · Inflammopharmacology · doi:10.1007/s10787-015-0239-y · Cited by 543
Visser, K., Katchamart, W., Loza, E., Martinez-Lopez, J. A., Salliot, C., Trudeau, J., Bombardier, C., Carmona, L., van der Heijde, D., Bijlsma, J. W. J., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.094474 · Cited by 491
Self-citation
Metadata
- Authors
- Katchamart, W., Trudeau, J., Phumethum, V, & Bombardier, C.
- Venue
- Annals of the Rheumatic Diseases
- Publisher
- Elsevier BV
- Published
- 2009-07
- Volume
- 68
- Issue
- 7
- Pages
- 1105-1112
- ISSN
- 0003-4967 (ISSN-L)
- OpenAlex
- W2123127083
- Cited by
- 177
- References
- 10
- FWCI
- 2.20
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.1136/ard.2008.099861
- The paper
- Katchamart, W., Trudeau, J., Phumethum, V, & Bombardier, C. (2009). Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. Annals of the Rheumatic Diseases. https://doi.org/10.1136/ard.2008.099861
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.